[{"address1": "65, quai Georges Gorse", "city": "Boulogne-Billancourt", "zip": "92100", "country": "France", "phone": "33 1 58 33 50 00", "fax": "33 1 58 33 50 01", "website": "https://www.ipsen.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.", "fullTimeEmployees": 5325, "companyOfficers": [{"maxAge": 1, "name": "Mr. David  Loew", "age": 56, "title": "MD, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 2362595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Aymeric  Le Chatelier", "age": 54, "title": "Executive VP & CFO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 817325, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Aidan  Murphy Ph.D.", "age": 57, "title": "Executive VP and Head of Technical Operations", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Craig  Marks", "title": "Vice-President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Francois  Garnier", "age": 61, "title": "Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Regis  Mulot", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dominique  Bery", "age": 52, "title": "Head of Nordics & Baltics", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bartosz  Bednarz D.D.S.", "title": "Executive VP and Head of Global Product & Portfolio Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Lopes-Fernandes CBO", "title": "Executive VP & Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Levine M.D., Ph.D.", "title": "President of Fondation Ipsen", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 30.35, "open": 30.35, "dayLow": 30.35, "dayHigh": 30.35, "regularMarketPreviousClose": 30.35, "regularMarketOpen": 30.35, "regularMarketDayLow": 30.35, "regularMarketDayHigh": 30.35, "dividendRate": 0.33, "dividendYield": 0.0108, "exDividendDate": 1717113600, "payoutRatio": 0.1517, "fiveYearAvgDividendYield": 1.21, "beta": 0.603, "trailingPE": 13.795454, "forwardPE": 2.664618, "volume": 1800, "regularMarketVolume": 1800, "averageVolume": 762, "averageVolume10days": 760, "averageDailyVolume10Day": 760, "bid": 29.54, "ask": 30.21, "bidSize": 40000, "askSize": 40000, "marketCap": 10039658496, "fiftyTwoWeekLow": 26.97, "fiftyTwoWeekHigh": 34.338, "priceToSalesTrailing12Months": 2.9226685, "fiftyDayAverage": 29.3913, "twoHundredDayAverage": 29.635365, "trailingAnnualDividendRate": 1.2, "trailingAnnualDividendYield": 0.039538715, "currency": "USD", "enterpriseValue": 2518714368, "profitMargins": 0.19830999, "floatShares": 28183857, "sharesOutstanding": 330796000, "heldPercentInstitutions": 8.9999994e-05, "bookValue": 48.842, "priceToBook": 0.6213914, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.189, "netIncomeToCommon": 663900032, "trailingEps": 2.2, "forwardEps": 11.39, "pegRatio": 0.56, "enterpriseToRevenue": 0.733, "enterpriseToEbitda": 2.201, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IPSEY", "underlyingSymbol": "IPSEY", "shortName": "Ipsen S.A.", "longName": "Ipsen S.A.", "firstTradeDateEpochUtc": 1344000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "92de0e8d-d82f-32c7-93a0-d2e703767a6d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 30.35, "recommendationKey": "none", "totalCash": 485400000, "totalCashPerShare": 5.858, "ebitda": 1144499968, "totalDebt": 490200000, "quickRatio": 0.798, "currentRatio": 1.141, "totalRevenue": 3435099904, "debtToEquity": 12.115, "revenuePerShare": 10.37225, "returnOnAssets": 0.084809996, "returnOnEquity": 0.17909999, "freeCashflow": 523862496, "operatingCashflow": 902499968, "earningsGrowth": 0.183, "revenueGrowth": 0.079, "grossMargins": 0.82009006, "ebitdaMargins": 0.33318, "operatingMargins": 0.18324, "financialCurrency": "EUR", "trailingPegRatio": 2.2581, "__fetch_time": "2024-09-05"}]